Early safety study of VK3019 for weight in adults with excess weight
Tests a new drug, VK3019, against placebo in adults with excess body weight.
Plain-language title generated from the registry record
Registry title: A Phase 1 Study of VK3019 in Overweight and Obese Adults Without Comorbidities
Key facts
- Where
- Lake Forest, United StatesSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07846033, who can take part
Where in United States
- Lake ForestLake Forest, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Viking Therapeutics, Inc.
- Trial code
- NCT07846033
- Record updated
- 29 September 2026
- Original description
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.Read full original descriptionShow less
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VK3019, an Amylin and Calcitonin Receptor Agonist, in Overweight and Obese Adults Without Comorbidities
This is a Phase 1, randomized, double-blind, placebo-controlled single ascending dose (SAD) study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of VK3019 in overweight and obese adults without comorbidities.
Inclusion: Must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF); Participants must be medically healthy, with no significant medical history, have no clinically significant abnormalities on physical examination at Screening and/or before administration of the initial dose of IP in the opinion of the Investigator; Body mass index ≥ 27 kg/m2 and < 40 kg/m2; Willing to comply with contraceptive requirements.
Exclusion: Current or prior diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes); Any surgical or medical condition (active or chronic) that may interfere with IP distribution, metabolism, excretion, or drug absorption; History or presence of clinically significant acute or unstable cerebrovascular (stroke), hepatic, renal, gastrointestinal, pulmonary, immunological, endocrine, diabetes, hematological, oncological, or central nervous disorder that in the opinion of the Investigator would pose a significant risk for the participant; History of, or current, clinically significant liver disease, gallbladder disease (with the exception of Gilbert's Syndrome), as assessed by the Investigator; History of drug or alcohol abuse (ie, >14 drinks/week for women or 21 drinks/week for men [1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor]) within 12 months of Screening; Participants with any level of disease or organ system dysfunction as identified during physical examination, medical history or laboratory testing, as assessed by the Investigator.